<DOC>
	<DOCNO>NCT02053220</DOCNO>
	<brief_summary>To assess pattern ColoAd1 viral delivery viral expression within colon tumour tissue administer intra-tumoural injection within colon , non-small cell lung , bladder renal cell tumour tissue follow ColoAd1 administration intravenous infusion .</brief_summary>
	<brief_title>Mechanism Action Trial ColoAd1</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Inclusion criterion : Patients must meet follow criterion eligible participation : Able willing provide write informed consent comply study protocol Age ≥ 18 year Patients histologically confirm resectable colon cancer , NSCLC ( squamous nonsquamous ) , bladder cancer ( urothelial cell carcinoma ) RCC ( renal cell carcinoma ) , schedule resection primary tumour plan resection drain lymph node colon cancer Diagnostic colonoscopy perform study centre ( Cohorts A B ) referral centre ( Cohort B ) report colonoscopy available study Tumour size 3 cm diameter estimate diagnostic colonoscopy cohorts A B CTscan cohort C , D E. At least 2 week since last dose intravenous systemic chemotherapy time first administration ColoAd1 Recovered Grade 1 effect ( exclude alopecia ) prior therapy malignancy . Able undergo surgery general anaesthesia Surgery plan administration ColoAd1 feasible within 15 day plan surgery ( follow IT administration follow first dose IV administration ) cohorts A B 10 25 day first ColoAd1 administration cohort C , D E ECOG Performance Status Score 0 1 Adequate renal function Creatinine ≤ 1.5 mg/dL calculate creatinine clearance use CockcroftGault formula ≥ 60 mL/min , measure creatinine clearance ≥60 mL/min , Absence clinically significant haematuria urinalysis : dipstick &lt; 2+ Absence clinically significant proteinuria urinalysis : dipstick &lt; 2+ . Adequate hepatic function serum bilirubin &lt; 1.5 x ULN AST ALT ≤ 3 x ULN Adequate bone marrow function : ANC ≥ 1.5 x 109/L , platelet ≥ 100 x 109/L , haemoglobin ≥ 90 g/L Adequate coagulation test : INR ≤ 1.5 x ULN ; For female childbearing potential ( define &lt; 2 year last menstruation surgically sterile ) , negative pregnancy test must document prior enrolment ; For woman postmenopausal ( 24 month amenorrhea ) surgically sterile ( absence ovary and/or uterus ) : agreement use two adequate method contraception , include least one method failure rate &lt; 1 % per year ( e.g. , hormonal implant , combine oral contraceptive , vasectomized partner ) , treatment period least 3 month last dose study drug ; For men : agreement use barrier method contraception treatment period least 6 month last dose study drug Exclusion Criteria patient : Patients meet follow criterion eligible enrolment : Rectal tumour ; ( cohorts A B ) ; An obstructive tumour intestine ( cohorts A B ) urinary tract ( cohort D ) ; Any condition necessitate surgery le 8 day ( cohorts A B ) 10 day ( cohort C , D E ) ; Pregnant lactating ( nurse ) woman ; Known and/or history evidence significant immunodeficiency due underlie illness ( e.g . HIV/AIDS ) and/or medication ( e.g . systemic corticosteroid dose high dexamethasone 10 mg equivalent , immunosuppressive medication include cyclosporine , azathioprine , interferon , within past 4 week ) ; Splenectomy Prior allogeneic autologous bone marrow organ transplantation Active infection require antibiotic , physician monitoring , recurrent fever &gt; 38.0 degree centigrade associate clinical diagnosis active infection Active viral disease , positive serology HIV , hepatitis B hepatitis C Use follow antiviral agent : ribavirin , adefovir , lamivudine cidofovir within 7 day prior day 1 ; PEGIFN ( within 14 day prior day 1 ) ; Administration investigational drug within 28 day prior first dose ColoAd1 Major surgery within 4 week radiotherapy within 3 week prior first dose ColoAd1 Another primary malignancy within past 3 year ( except nonmelanoma skin cancer cervical cancer situ ) Known CNS metastasis Inflammatory diseases bowel ( cohorts A B ) inflammatory disease may require treatment corticosteroid . Any condition illness , opinion Investigator medical monitor , would compromise patient safety interfere evaluation safety drug Known allergy treatment medication excipients Any medical psychological condition would preclude participation study compromise ability give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>